US Patent

US9506058 — Compositions for treating muscular dystrophy

Method of Use · Assigned to Sarepta Therapeutics Inc · Expires 2034-03-14 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects improved compositions and methods for treating muscular dystrophy using antisense molecules that induce exon skipping in the human dystrophin gene.

USPTO Abstract

Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.

Drugs covered by this patent

Exondys 51 (ETEPLIRSEN) · Sarepta

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1918`	—	Exondys 51
`U-1918`	—	Exondys 51

Patent Metadata

Patent number: US9506058
Jurisdiction: US
Classification: Method of Use
Expires: 2034-03-14
Drug substance claim: No
Drug product claim: No
Assignee: Sarepta Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.